Author Page for Massimo Andreoni

First Evidence of Pathogenic HERV-W Envelope Expression in T Lymphocytes in Association with the Respiratory Outcome of COVID-19 Patients

Number of pages: 23 Posted: 11 Jan 2021

Emanuela Balestrieri, Antonella Minutolo, Vita Petrone, Marialaura Fanelli, Marco Iannetta, Vincenzo Malagnino, Marta Zordan, Pietro Vitale, Benjamin Charvet, Branka Horvat, Sergio Bernardini, Enrico Garaci, Paolo Di Francesco, Paola Sinibaldi Vallebona, Loredana Sarmati, Sandro Grelli, Massimo Andreoni, Hervé Perron and Claudia Matteucci

University of Rome Tor Vergata - Department of Experimental Medicine, University of Rome Tor Vergata - Department of Experimental Medicine, University of Rome Tor Vergata - Department of Experimental Medicine, University of Rome Tor Vergata - Department of Experimental Medicine, University of Rome Tor Vergata - Department of Systems Medicine, University of Rome Tor Vergata - Department of Systems Medicine, University of Rome Tor Vergata - Department of Systems Medicine, University of Rome Tor Vergata - Infectious Diseases Clinic, ENS Lyon - International Center for Infectiology Research (CIRI), ENS Lyon - International Center for Infectiology Research (CIRI), University of Rome Tor Vergata - Department of Experimental Medicine, IRCCS San Raffaele Pisana, University of Rome Tor Vergata - Department of Experimental Medicine, University of Rome Tor Vergata - Department of Experimental Medicine, University of Rome Tor Vergata - Department of Systems Medicine, University of Rome Tor Vergata - Department of Experimental Medicine, University of Rome Tor Vergata - Faculty of Medicine and Surgery, Geneuro – Innovation and University of Rome Tor Vergata - Department of Experimental Medicine

Downloads 152 (488,442)

Citation 1

Abstract:

2.

Health Policy Model: Long-Term Predictive Results Associated with the Management of HCV-Induced Diseases in Italy

CEIS Working Paper No. 308

Number of pages: 18 Posted: 18 Feb 2014 Last Revised: 19 Feb 2014

Francesco Mennini, Andrea Marcellusi, Massimo Andreoni, Antonio Gasbarrini, Salvatore Salomone and Antonio Craxì

University of Rome Tor Vergata - Centre for International Studies on Economic Growth (CEIS), University of Rome Tor Vergata - Centre for International Studies on Economic Growth (CEIS), University of Rome Tor Vergata - Faculty of Medicine and Surgery, Catholic University of the Sacred Heart, Rome, University of Catania and - Section of Gastroenterology and Hepatology

Downloads 135 (540,814)

Citation 2

Abstract:

3.

Comparative Analysis of Early COVID-19 Treatment Efficacy in a Multicentric Regional Cohort in Italy: Emulation of a Series of Target Trials

TLRHEUROPE-D-24-00554, https://doi.org/10.2139/ssrn.4901222

Number of pages: 19 Posted: 07 Aug 2024

Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University College London - Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Clinical Division of Infectious Diseases, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Catholic University of Milan, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Clinical Department, University of Rome Tor Vergata, Sapienza University of Rome, Sapienza University of Rome, University of Udine, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Università Cattolica del Sacro Cuore, Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Translational Research Unit, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University of Rome Tor Vergata, Sapienza University of Rome - Department of Public Health and Infectious Diseases, University of Rome Tor Vergata - Faculty of Medicine and Surgery, Magna Graecia University of Catanzaro - Department of Medical and Surgical Sciences, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Laboratory of Virology, Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Clinical Department and Independent

Downloads 102 (679,608)

Abstract:

4.

Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study)

Number of pages: 38 Posted: 05 Dec 2022

Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Fondazione Policlinico Universitario A. Gemelli IRCCS - Section of Infectious Diseases, ASST Santi Paolo e Carlo, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Fondazione Policlinico Universitario A. Gemelli IRCCS, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Fondazione Policlinico Universitario A. Gemelli IRCCS - Section of Infectious Diseases, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, ASST Santi Paolo e Carlo, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University of Rome Tor Vergata - Department of Systems Medicine, affiliation not provided to SSRN, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University of Rome Tor Vergata - Faculty of Medicine and Surgery, University of Rome Tor Vergata - Department of Systems Medicine, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University of Milan - Clinic of Infectious Diseases and Tropical Medicine, Lazzaro Spallanzani National Institute for Infectious Diseases, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Clinical Department and Independent

Downloads 64 (924,743)

Massimo Andreoni

University of Rome Tor Vergata - Faculty of Medicine and Surgery

4

453

3

Scholarly Papers (4)

First Evidence of Pathogenic HERV-W Envelope Expression in T Lymphocytes in Association with the Respiratory Outcome of COVID-19 Patients

Abstract:

Health Policy Model: Long-Term Predictive Results Associated with the Management of HCV-Induced Diseases in Italy

Abstract:

Comparative Analysis of Early COVID-19 Treatment Efficacy in a Multicentric Regional Cohort in Italy: Emulation of a Series of Target Trials

Abstract:

Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study)

Abstract: